EricHauraMD

Associate Professor, Oncologic Sciences, USF-Morsani

Overview of Dr. Haura

Dr. Eric Haura is an oncologist in Tampa, FL and is affiliated with H. Lee Moffitt Cancer Center and Research Institute. He received his medical degree from Duke University School of Medicine and has been in practice 23 years. Dr. Haura accepts several types of health insurance, listed below. He is one of 170 doctors at H. Lee Moffitt Cancer Center and Research Institute who specialize in Oncology. He has more than 100 publications and over 500 citings.

Office
12902 Usf Magnolia Dr
Tampa, FL 33612
Book by Phone+1(267) 314-8048

Fax+1 813-745-6817

Education & Training

Duke University HospitalFellowship, Hematology and Medical Oncology, 1997 - 2000
Johns Hopkins UniversityResidency, Internal Medicine, 1994 - 1997
Duke University School of MedicineClass of 1994

Certifications & Licensure

FL State Medical License 2000 - 2025
NC State Medical License 1999 - 2001
American Board of Internal Medicine Medical Oncology

Clinical Trials

Neoadjuvant IRESSA As Single Agent PreopTherapy for NSCLC With Molecular Correlates Start of enrollment: 2004 Oct 01
Terminated
Not Applicable
Phase I Dasatinib/Erlotinib in Recurrent Non-small Cell Lung Cancer (NSCLC) Start of enrollment: 2007 Mar 01
Completed
Phase 1
Dasatinib in Advanced Non-small Cell Lung Cancer (NSCL) With Ex Vivo and In Vivo Assessment of Tumor Target Modulation Start of enrollment: 2009 Mar 01
Terminated
Phase 2
Combination Immunotherapy of GM.CD40L Vaccine With CCL21 in Lung Cancer Start of enrollment: 2012 Mar 26
Completed
Phase 1, Phase 2
Smoking Relapse-Prevention Intervention for Cancer Patients Start of enrollment: 2012 Jan 04
Completed
Not Applicable
A Phase I/IB Trial of MEK162 in Combination With Erlotinib in NSCLC Harboring KRAS or EGFR Mutation Start of enrollment: 2013 Dec 30
Completed
Phase 1
A Study of Emibetuzumab in Non Small Cell Lung Cancer (NSCLC) Participants Start of enrollment: 2013 Aug 01
Completed
Phase 2
Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC) Start of enrollment: 2013 Dec 31
Completed
Phase 1
Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC Start of enrollment: 2019 Feb 01
Active, not recruiting
Phase 1
Immune Checkpoint Inhibition With Lurbinectedin Relapsed/Recurrent SCLC Start of enrollment: 2020 Nov 23
Terminated
Phase 1
Join now to see all

Publications & Presentations

PubMed

49 citations
Phosphoproteomics reveals MAPK inhibitors enhance MET- and EGFR-driven AKT signaling in KRAS-mutant lung cancer.
Jae-Young Kim, Eric A. Welsh, Bin Fang, Yun Bai, Fumi Kinose
Molecular Cancer Research. 2016-07-15
179 citations
Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival.
Lanxi Song, Mark R. Morris, Tapan K. Bagui, Francis Y.F. Lee, Richard Jove
Cancer Research. 2006-06-01
347 citations
Mechanisms of Disease: insights into the emerging role of signal transducers and activators of transcription in cancer
Eric B. Haura, James Turkson, Richard Jove
Nature Clinical Practice. Oncology. 2005-06-01

Abstracts/Posters

Bromodomain and Extra Terminal Domain (BET) Inhibitors Sensitize Chronic Myelomonocytic Leukemia (CMML) to PIM Inhibition Via Downregulation of Mir-33a
Eric B. Haura, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

JNJ-61186372 (JNJ-372), an EGFR-cMet bispecific antibody, in EGFR-driven advanced non-small cell lung cancer (NSCLC).
2019 ASCO Annual Meeting - 6/1/2019

Press Mentions

Adoptive Cell Therapy plus Checkpoint Inhibitors Show Promise in Non-Small Cell Lung CancerAugust 12th, 2021
Moffitt Gets $10.2 Million Grant to Develop Lung Cancer TreatmentsJune 29th, 2021
The Rapid Tissue Donation Program at Moffitt Cancer Center Offers a Feasible Approach to Improve ResearchDecember 13th, 2019
Join now to see all

Insurance Accepted

Aetna Choice POS II
Aetna HMO
AvMed Health Open Access
BCBS Blue Card PPO
BCBS California PPO
BCBS Florida BlueCare HMO
BCBS Florida NetworkBlue
BCBS Florida Preferred Patient Care PPO
Blue Shield California PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Cofinity PPO
Coventry Florida - Employer Group PPO
First Health PPO
Great West PPO
Humana ChoiceCare Network PPO
Multiplan PHCS PPO
Multiplan PHCS PPO - Kaiser
Multiplan PPO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
Please verify your coverage with the provider's office directly when scheduling an appointment